tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Value
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Smart Value
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

TRVI Stock Latest News

Trevi Therapeutics’ Earnings Call: Clinical Success Amid Financial Challenges
Company AnnouncementsTrevi Therapeutics’ Earnings Call: Clinical Success Amid Financial Challenges
4d ago
TRVI
Trevi Therapeutics Stock (TRVI) Surges Over 60% on Promising Trial Results and Q4 Financials
PremiumMarket News
Trevi Therapeutics Stock (TRVI) Surges Over 60% on Promising Trial Results and Q4 Financials
6d ago
TRVI
Trevi Therapeutics price target raised to $20 from $11 at B. Riley
PremiumThe Fly
Trevi Therapeutics price target raised to $20 from $11 at B. Riley
7d ago
TRVI
Trevi Therapeutics’ Promising Prospects: Buy Rating Backed by Positive Trial Results and Market Potential
PremiumRatings
Trevi Therapeutics’ Promising Prospects: Buy Rating Backed by Positive Trial Results and Market Potential
7d ago
TRVI
Trevi Therapeutics’ Haduvio: Promising Developments and Strategic Advancements Reinforce Buy Rating
PremiumRatings
Trevi Therapeutics’ Haduvio: Promising Developments and Strategic Advancements Reinforce Buy Rating
7d ago
TRVI
Trevi Therapeutics: Buy Rating Backed by Promising Haduvio Trial Results and Strong Market Potential
PremiumRatingsTrevi Therapeutics: Buy Rating Backed by Promising Haduvio Trial Results and Strong Market Potential
7d ago
TRVI
Trevi Therapeutics Advances Haduvio in Clinical Trials
Premium
Company Announcements
Trevi Therapeutics Advances Haduvio in Clinical Trials
7d ago
TRVI
Trevi Therapeutics reports Q4 EPS (11c), consensus (12c)
Premium
The Fly
Trevi Therapeutics reports Q4 EPS (11c), consensus (12c)
8d ago
TRVI
Trevi Therapeutics options imply 7.8% move in share price post-earnings
PremiumThe Fly
Trevi Therapeutics options imply 7.8% move in share price post-earnings
8d ago
TRVI
Trevi Therapeutics added to Analyst Current Favorites list at Raymond James
PremiumThe Fly
Trevi Therapeutics added to Analyst Current Favorites list at Raymond James
8d ago
TRVI
Trevi Therapeutics: Buy Rating Amid Promising Haduvio Trial Prospects and Strong Market Potential
PremiumRatings
Trevi Therapeutics: Buy Rating Amid Promising Haduvio Trial Prospects and Strong Market Potential
8d ago
TRVI
Trevi Therapeutics (TRVI) Q4 Earnings Cheat Sheet
PremiumPre-Earnings
Trevi Therapeutics (TRVI) Q4 Earnings Cheat Sheet
10d ago
TRVI
Largest borrow rate increases among liquid names
PremiumThe FlyLargest borrow rate increases among liquid names
12d ago
WW
FRO
Biotech Alert: Searches spiking for these stocks today
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
14d ago
AEON
APRE
Trevi Therapeutics price target raised to $20 from $12 at Oppenheimer
Premium
The Fly
Trevi Therapeutics price target raised to $20 from $12 at Oppenheimer
15d ago
TRVI
Trevi Therapeutics price target raised to $12.50 from $7.50 at H.C. Wainwright
PremiumThe Fly
Trevi Therapeutics price target raised to $12.50 from $7.50 at H.C. Wainwright
16d ago
TRVI
Haduvio’s Promising Efficacy in RCC Drives Buy Rating and Increased Price Target
PremiumRatings
Haduvio’s Promising Efficacy in RCC Drives Buy Rating and Increased Price Target
16d ago
TRVI
Trevi Therapeutics price target raised to $11 from $7 at Leerink
PremiumThe Fly
Trevi Therapeutics price target raised to $11 from $7 at Leerink
16d ago
TRVI
Trevi Therapeutics price target raised to $25 from $8 at Needham
PremiumThe Fly
Trevi Therapeutics price target raised to $25 from $8 at Needham
16d ago
TRVI
Trevi Therapeutics upgraded to Strong Buy from Outperform at Raymond James
PremiumThe FlyTrevi Therapeutics upgraded to Strong Buy from Outperform at Raymond James
16d ago
GSK
TRVI
Trevi Therapeutics RIVER trial meets primary endpoint
Premium
The Fly
Trevi Therapeutics RIVER trial meets primary endpoint
16d ago
TRVI
Trevi Therapeutics completes enrollment for Phase 2b trial of Haduvio in cough
Premium
The Fly
Trevi Therapeutics completes enrollment for Phase 2b trial of Haduvio in cough
29d ago
TRVI

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >